DB04968InvestigationalSmall molecule
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
- Mechanism
- Curator reviewed
There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.
- Primary indication
- Intended for the acute treatment of social phobia.Curator reviewed
- Code names
- PH94B
Resolves to
Compound
What you can answer from here — as of May 29, 2025
Which companies are running trials of Fasedienol, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account